OncoTargets and Therapy (Feb 2017)

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas

  • Recine F,
  • Bongiovanni A,
  • Riva N,
  • Fausti V,
  • De Vita A,
  • Mercatali L,
  • Liverani C,
  • Miserocchi G,
  • Amadori D,
  • Ibrahim T

Journal volume & issue
Vol. Volume 10
pp. 1155 – 1164

Abstract

Read online

Federica Recine, Alberto Bongiovanni, Nada Riva, Valentina Fausti, Alessandro De Vita, Laura Mercatali, Chiara Liverani, Giacomo Miserocchi, Dino Amadori, Toni Ibrahim Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy Abstract: Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers. This group of tumors comprises over 60 different histotypes with different biology showing different sensitivity to therapeutic agents. For decades, the standard first-line systemic treatment of metastatic STS has comprised anthracycline based-chemotherapy. Second-line therapy options include agents such as ifosfamide, gemcitabine, and pazopanib, but the optimal sequential therapy for the management of metastatic disease has yet to be defined. Trabectedin is one of the new molecules approved for patients in progression after first-line chemotherapy with anthracyclines or for those unfit for these agents. The compound is characterized by multiple potential mechanisms of action combining cytotoxic, targeted, and immunological effects. This article takes an in-depth look at the role of trabectedin in the management of metastatic STS, including L-sarcoma and non-L-sarcoma. Keywords: soft tissue sarcoma, histotypes, chemotherapy, L-sarcomas, non-L-sarcomas

Keywords